Evidence map›Paper›PMID 40159464›Full record

ArticleCancer science2025

Dual Targeting of Aurora-A and Bcl-xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer.

Mingxue Liu, Jing Guo, Weiyong Liu, Zhenye Yang, Fazhi Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingxue LiuDepartment of Ultrasound, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Jing GuoDepartment of Ultrasound, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Weiyong LiuDepartment of Ultrasound, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Zhenye YangKey Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Fazhi YuKey Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID https://orcid.org/0000-0001-8586-0998

Funding

National Key RD Program of China 2022YFA1303100National Science Foundation of China 32170736National Science Foundation of China 32370776National Science Foundation of China 92357301Noncommunicable Chronic Diseases National Science and Technology Major Project 2023ZD0507500Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of IHM of USTC QYPY20220017The Fundamental Research Funds for the Central Universities YD9100002011
6 · The paper itself

Abstract

The Aurora-A kinase inhibitor MLN8237 has shown efficacy in clinical trials for advanced breast cancer; however, its use as a monotherapy is limited by significant side effects and modest efficacy. Therefore, combining MLN8237 with other agents at lower doses may provide a viable alternative. In this study, we evaluated the combination of MLN8237 with the BH3 mimetic ABT263 for the treatment of triple-negative breast cancer (TNBC). We found that this combination significantly suppressed tumor growth and metastasis in immunocompetent syngeneic mouse models, whereas its efficacy was attenuated in immunodeficient xenograft models. Mechanistic studies revealed that the combination enhanced anti-tumor immunity by increasing the presence of CD8

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisAurora Kinase AAzepinesbcl-X ProteinPyrimidinesSulfonamidesTriple Negative Breast NeoplasmsTumor MicroenvironmentAniline CompoundsAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationDrug SynergismFemaleAniline CompoundsAurora Kinase AAzepinesBCL2L1 protein, humanbcl-X ProteinMLN 8237Myeloid Cell Leukemia Sequence 1 ProteinnavitoclaxPyrimidinesSulfonamidesapoptosisAurora‐ABcl‐xLsynergistic therapytumor immune microenvironment

Identifiers

PMID40159464
PMCPMC12210044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.